Tuberculosis Testing Market by Test Type (Culture Test, Immunological Test, Molecular Test), Technology (Culture Based Technology, Immunodiagnostic, Lipoarabinomannan Assay), Sample Type, End User, Distribution Channel, Application - Global Forecast 2025-
Description
The Tuberculosis Testing Market was valued at USD 2.22 billion in 2024 and is projected to grow to USD 2.35 billion in 2025, with a CAGR of 6.50%, reaching USD 3.68 billion by 2032.
A strategic introduction that frames tuberculosis testing priorities, diagnostic modalities, clinical constraints, and the study focus for decision-makers
This executive summary opens with a clear framing of why tuberculosis testing remains a strategic priority for public health systems and clinical laboratories. Recent advances in molecular diagnostics, expanded access to rapid antigen-style assays, and renewed global attention to tuberculosis control have combined to create a diagnostic environment that demands both precision and agility. Clinicians and laboratory managers now balance traditional culture-based confirmation with faster nucleic acid amplification techniques to optimize patient pathways and infection control measures.
The introduction sets the scope of analysis by outlining core diagnostic modalities, typical end users, and the technological vectors driving innovation. It clarifies the intended audience, which includes laboratory directors, procurement leads, clinical program managers, and policy advisers who require an evidence-based synthesis to inform procurement, implementation, and clinical workflow redesign. The section also highlights key constraints such as sample variability, biosafety requirements, and regulatory heterogeneity that influence adoption timelines and operational complexity.
Transformative shifts in tuberculosis diagnostics driven by molecular decentralization, improved sample processing, and point-of-care innovations
The diagnostic landscape for tuberculosis has undergone transformative shifts shaped by technological maturation, changing clinical workflows, and evolving public health priorities. Molecular platforms that deliver rapid nucleic acid amplification results at decentralized sites are reshaping diagnostic algorithms, reducing time to treatment initiation and enabling more targeted use of second-line therapies when resistance is detected. At the same time, innovations in sample preparation and point-of-care devices have expanded the ability to test outside centralized laboratories, which alters referral patterns and resource allocation for hospital networks and clinics.
Concurrently, immunodiagnostic enhancements, including improved ELISA formats and refinements in confirmatory Western blot techniques, continue to play a role in specific clinical contexts, particularly where molecular access is limited. Culture methods remain the reference standard for complex cases and resistance profiling, yet liquid culture systems are evolving to reduce turnaround times. Rapid chromatographic and lateral flow assays provide pragmatic screening options, especially in high-burden or resource-constrained environments where immediate clinical decisions are required. Together, these shifts necessitate integrated diagnostic strategies that account for sensitivity, specificity, throughput, biosafety, and the realities of end-user capacities.
Cumulative implications of United States 2025 tariff measures on tuberculosis diagnostic procurement, supply chain resilience, and operational continuity
The implementation of tariffs in 2025 introduced new layers of complexity across the diagnostic supply chain, provoking immediate operational and procurement responses among laboratories and healthcare systems. Tariff-related cost pressures have encouraged organizations to reassess supplier diversity, negotiate longer-term contracts to stabilize pricing, and explore regional procurement consortia to dilute single-supplier exposure. Procurement teams have prioritized instruments and consumables that offer predictable total cost of ownership, consistent reagent stability, and vendor-managed inventory options to mitigate tariff volatility.
Operationally, some laboratories have altered stocking patterns for critical reagents and shifted toward greater inventory buffers to avoid supply interruptions. Regulatory affairs and import specialists report a renewed emphasis on domestic certification pathways and accelerated qualification of alternative suppliers to maintain clinical continuity. Over the medium term, manufacturers and distributors are responding with strategic adjustments that include partial onshoring of assembly operations, optimized freight routing, and revised pricing strategies to preserve market access and minimize downstream clinical impact. These adaptations underscore the importance of supply chain resilience as an operational priority for diagnostic services.
Comprehensive segmentation insights that connect test types, end-user environments, technologies, sample types, distribution channels, and clinical applications
Segmentation analysis reveals how diagnostic choices and end-user contexts interact to shape adoption patterns and procurement priorities. Based on test type, diagnostic pathways include Culture Test, Immunological Test, Molecular Test, and Rapid Diagnostic Test; within culture modalities, liquid culture and solid culture each serve distinct clinical use cases where liquid culture often supports faster detection and solid culture retains a role in confirmatory workflows. Immunological testing, typified by ELISA and Western blot approaches, remains relevant for specific immunological assessments and confirmatory testing, while molecular options such as Line Probe Assay and PCR are the primary drivers of rapid resistance detection and early therapeutic decision-making. Rapid diagnostic formats, including chromatographic and lateral flow technologies, are increasingly used for point-of-care screening where immediate triage is essential.
End users span clinics, hospitals, and reference laboratories, and their differing throughput requirements, biosafety capabilities, and clinical objectives determine the optimal diagnostic mix. From a technology perspective, culture-based technology, immunodiagnostic platforms, the lipoarabinomannan assay, and nucleic acid amplification tests each contribute unique sensitivity and operational profiles that inform deployment decisions. Sample type considerations-blood, sputum, and urine-further influence test selection, as some assays perform optimally with respiratory specimens while others enable extrapulmonary screening. Distribution channel dynamics through diagnostic laboratories, hospital pharmacies, and online pharmacies affect accessibility and procurement cadence. Finally, application differentiation between active tuberculosis and latent tuberculosis drives the clinical utility of specific tests and the prioritization of confirmatory versus screening strategies. Taken together, these segmentation layers create a nuanced view of where investment, training, and infrastructure upgrades will yield the greatest clinical and operational benefits.
Key regional diagnostic dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, procurement, and operational strategies
Regional dynamics shape diagnostic priorities and investment patterns across diverse healthcare systems, with distinct opportunities and constraints in each geography. In the Americas, diagnostic networks balance urban tertiary centers with remote clinics, emphasizing scalable molecular platforms and rapid assays to support concentrated public health initiatives and complex referral pathways. Reimbursement frameworks and regulatory timelines in this region influence the pace of adoption and favor solutions that integrate with existing laboratory information systems and electronic health records.
Europe, Middle East & Africa presents heterogenous settings where national laboratory capacities, procurement mechanisms, and public health strategies vary widely; centralized reference laboratories coexist with point-of-care needs in underserved areas, prompting a mixed-technology approach that includes culture-based confirmation and decentralized rapid testing. Asia-Pacific combines large high-burden countries with advanced manufacturing hubs and strong private sector laboratory networks, which accelerates uptake of next-generation molecular tests and drives innovation in sample preparation, cost-efficient manufacturing, and local validation efforts. Understanding these regional distinctions is essential for tailoring deployment strategies, regulatory engagement, and commercial approaches that align with local clinical and public health priorities.
Strategic behaviors and portfolio adjustments among leading diagnostic companies focusing on interoperability, supply reliability, and clinical evidence generation
Leading diagnostic companies are reshaping portfolios to address the broad spectrum of tuberculosis testing needs, emphasizing interoperability, reagent stability, and scalable workflows. Many firms are investing in modular platforms that support both nucleic acid amplification and immunodiagnostic assays to maximize instrument utilization across different clinical scenarios. Strategic partnerships between device manufacturers, reagent suppliers, and logistics firms aim to reduce lead times and ensure consistency of supply, while research collaborations with academic centers accelerate validation of novel biomarkers and sample processing protocols.
In addition, product strategy increasingly incorporates service and maintenance models that reduce total cost of ownership for high-throughput laboratories and strengthen adoption in resource-limited settings. Regulatory engagement and post-market surveillance have become differentiating activities, with companies investing in real-world evidence generation and clinical utility studies to support payer conversations and public health procurement. Competitive positioning also reflects a balance between pushing for novel assay innovations and sustaining robust support for legacy platforms that remain essential to many laboratory networks.
Actionable recommendations for industry leaders to integrate rapid molecular detection with confirmatory workflows, strengthen supply chains, and accelerate clinical adoption
Industry leaders should prioritize integrated diagnostic strategies that marry rapid molecular detection with confirmatory culture workflows to ensure both immediate clinical action and comprehensive resistance profiling. Investments in decentralized nucleic acid amplification platforms and enhanced sample-prep methods will reduce time to treatment and improve patient outcomes, while institutional commitment to biosafety and staff training will protect both patients and laboratory personnel.
Supply chain diversification and stronger contractual frameworks should be implemented to mitigate tariff-related and logistics risks. Engaging with regional regulatory authorities early in the product lifecycle and investing in post-market evidence generation will accelerate reimbursement and adoption. Health systems should also evaluate distribution models that leverage diagnostic laboratories, hospital pharmacies, and online procurement channels to expand access while maintaining quality controls. Finally, manufacturers and health systems can collaborate on pilot implementations that demonstrate clinical utility in real-world pathways, creating the evidence base needed to scale solutions sustainably.
A rigorous mixed-methods research methodology combining primary stakeholder interviews, secondary literature synthesis, and robust validation to ensure actionable findings
This research synthesizes primary stakeholder input, secondary scientific literature, regulatory documents, and validated device specifications to produce a rigorous and transparent methodology. Primary research included structured interviews with laboratory directors, clinical microbiologists, procurement leads, and regulatory affairs specialists to capture operational realities, procurement constraints, and evidence requirements. Secondary sources comprised peer-reviewed articles, clinical guidelines, and publicly available regulatory filings that informed technology assessments and clinical performance characterization.
Data triangulation and cross-validation ensured consistency across information sources, with particular attention to assay sensitivity profiles, sample-type performance, and biosafety implications. The methodology incorporated qualitative analysis to interpret adoption barriers and enablers, and it applied a risk assessment framework to evaluate supply chain vulnerabilities and regulatory complexity. Quality control measures included expert review panels and iterative validation of key findings with frontline clinical stakeholders to ensure relevance and accuracy for decision-makers.
Conclusion synthesizing technological advances, operational imperatives, and strategic priorities to translate diagnostic innovations into clinical and public health impact
In conclusion, the tuberculosis testing environment is at an inflection point where technological possibility meets operational necessity. Advances in nucleic acid amplification, point-of-care rapid assays, and improvements in immunodiagnostics and culture workflows offer multiple avenues to accelerate diagnosis and optimize treatment pathways. However, realizing these benefits requires coordinated investment in laboratory capacity, workforce training, supply chain resilience, and regulatory engagement to translate innovative assays into routine clinical practice.
Decision-makers should approach diagnostic strategy holistically, integrating rapid screening with confirmatory testing, aligning procurement with operational capabilities, and building the evidence base needed for reimbursement and public health adoption. The interplay between regional dynamics, tariff pressures, and technological choices underscores the need for flexible strategies that are responsive to local constraints while leveraging global innovations. Ultimately, actionable planning and collaborative execution will determine the degree to which diagnostic advances translate into measurable improvements in patient outcomes and public health impact.
Please Note: PDF & Excel + Online Access - 1 Year
A strategic introduction that frames tuberculosis testing priorities, diagnostic modalities, clinical constraints, and the study focus for decision-makers
This executive summary opens with a clear framing of why tuberculosis testing remains a strategic priority for public health systems and clinical laboratories. Recent advances in molecular diagnostics, expanded access to rapid antigen-style assays, and renewed global attention to tuberculosis control have combined to create a diagnostic environment that demands both precision and agility. Clinicians and laboratory managers now balance traditional culture-based confirmation with faster nucleic acid amplification techniques to optimize patient pathways and infection control measures.
The introduction sets the scope of analysis by outlining core diagnostic modalities, typical end users, and the technological vectors driving innovation. It clarifies the intended audience, which includes laboratory directors, procurement leads, clinical program managers, and policy advisers who require an evidence-based synthesis to inform procurement, implementation, and clinical workflow redesign. The section also highlights key constraints such as sample variability, biosafety requirements, and regulatory heterogeneity that influence adoption timelines and operational complexity.
Transformative shifts in tuberculosis diagnostics driven by molecular decentralization, improved sample processing, and point-of-care innovations
The diagnostic landscape for tuberculosis has undergone transformative shifts shaped by technological maturation, changing clinical workflows, and evolving public health priorities. Molecular platforms that deliver rapid nucleic acid amplification results at decentralized sites are reshaping diagnostic algorithms, reducing time to treatment initiation and enabling more targeted use of second-line therapies when resistance is detected. At the same time, innovations in sample preparation and point-of-care devices have expanded the ability to test outside centralized laboratories, which alters referral patterns and resource allocation for hospital networks and clinics.
Concurrently, immunodiagnostic enhancements, including improved ELISA formats and refinements in confirmatory Western blot techniques, continue to play a role in specific clinical contexts, particularly where molecular access is limited. Culture methods remain the reference standard for complex cases and resistance profiling, yet liquid culture systems are evolving to reduce turnaround times. Rapid chromatographic and lateral flow assays provide pragmatic screening options, especially in high-burden or resource-constrained environments where immediate clinical decisions are required. Together, these shifts necessitate integrated diagnostic strategies that account for sensitivity, specificity, throughput, biosafety, and the realities of end-user capacities.
Cumulative implications of United States 2025 tariff measures on tuberculosis diagnostic procurement, supply chain resilience, and operational continuity
The implementation of tariffs in 2025 introduced new layers of complexity across the diagnostic supply chain, provoking immediate operational and procurement responses among laboratories and healthcare systems. Tariff-related cost pressures have encouraged organizations to reassess supplier diversity, negotiate longer-term contracts to stabilize pricing, and explore regional procurement consortia to dilute single-supplier exposure. Procurement teams have prioritized instruments and consumables that offer predictable total cost of ownership, consistent reagent stability, and vendor-managed inventory options to mitigate tariff volatility.
Operationally, some laboratories have altered stocking patterns for critical reagents and shifted toward greater inventory buffers to avoid supply interruptions. Regulatory affairs and import specialists report a renewed emphasis on domestic certification pathways and accelerated qualification of alternative suppliers to maintain clinical continuity. Over the medium term, manufacturers and distributors are responding with strategic adjustments that include partial onshoring of assembly operations, optimized freight routing, and revised pricing strategies to preserve market access and minimize downstream clinical impact. These adaptations underscore the importance of supply chain resilience as an operational priority for diagnostic services.
Comprehensive segmentation insights that connect test types, end-user environments, technologies, sample types, distribution channels, and clinical applications
Segmentation analysis reveals how diagnostic choices and end-user contexts interact to shape adoption patterns and procurement priorities. Based on test type, diagnostic pathways include Culture Test, Immunological Test, Molecular Test, and Rapid Diagnostic Test; within culture modalities, liquid culture and solid culture each serve distinct clinical use cases where liquid culture often supports faster detection and solid culture retains a role in confirmatory workflows. Immunological testing, typified by ELISA and Western blot approaches, remains relevant for specific immunological assessments and confirmatory testing, while molecular options such as Line Probe Assay and PCR are the primary drivers of rapid resistance detection and early therapeutic decision-making. Rapid diagnostic formats, including chromatographic and lateral flow technologies, are increasingly used for point-of-care screening where immediate triage is essential.
End users span clinics, hospitals, and reference laboratories, and their differing throughput requirements, biosafety capabilities, and clinical objectives determine the optimal diagnostic mix. From a technology perspective, culture-based technology, immunodiagnostic platforms, the lipoarabinomannan assay, and nucleic acid amplification tests each contribute unique sensitivity and operational profiles that inform deployment decisions. Sample type considerations-blood, sputum, and urine-further influence test selection, as some assays perform optimally with respiratory specimens while others enable extrapulmonary screening. Distribution channel dynamics through diagnostic laboratories, hospital pharmacies, and online pharmacies affect accessibility and procurement cadence. Finally, application differentiation between active tuberculosis and latent tuberculosis drives the clinical utility of specific tests and the prioritization of confirmatory versus screening strategies. Taken together, these segmentation layers create a nuanced view of where investment, training, and infrastructure upgrades will yield the greatest clinical and operational benefits.
Key regional diagnostic dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, procurement, and operational strategies
Regional dynamics shape diagnostic priorities and investment patterns across diverse healthcare systems, with distinct opportunities and constraints in each geography. In the Americas, diagnostic networks balance urban tertiary centers with remote clinics, emphasizing scalable molecular platforms and rapid assays to support concentrated public health initiatives and complex referral pathways. Reimbursement frameworks and regulatory timelines in this region influence the pace of adoption and favor solutions that integrate with existing laboratory information systems and electronic health records.
Europe, Middle East & Africa presents heterogenous settings where national laboratory capacities, procurement mechanisms, and public health strategies vary widely; centralized reference laboratories coexist with point-of-care needs in underserved areas, prompting a mixed-technology approach that includes culture-based confirmation and decentralized rapid testing. Asia-Pacific combines large high-burden countries with advanced manufacturing hubs and strong private sector laboratory networks, which accelerates uptake of next-generation molecular tests and drives innovation in sample preparation, cost-efficient manufacturing, and local validation efforts. Understanding these regional distinctions is essential for tailoring deployment strategies, regulatory engagement, and commercial approaches that align with local clinical and public health priorities.
Strategic behaviors and portfolio adjustments among leading diagnostic companies focusing on interoperability, supply reliability, and clinical evidence generation
Leading diagnostic companies are reshaping portfolios to address the broad spectrum of tuberculosis testing needs, emphasizing interoperability, reagent stability, and scalable workflows. Many firms are investing in modular platforms that support both nucleic acid amplification and immunodiagnostic assays to maximize instrument utilization across different clinical scenarios. Strategic partnerships between device manufacturers, reagent suppliers, and logistics firms aim to reduce lead times and ensure consistency of supply, while research collaborations with academic centers accelerate validation of novel biomarkers and sample processing protocols.
In addition, product strategy increasingly incorporates service and maintenance models that reduce total cost of ownership for high-throughput laboratories and strengthen adoption in resource-limited settings. Regulatory engagement and post-market surveillance have become differentiating activities, with companies investing in real-world evidence generation and clinical utility studies to support payer conversations and public health procurement. Competitive positioning also reflects a balance between pushing for novel assay innovations and sustaining robust support for legacy platforms that remain essential to many laboratory networks.
Actionable recommendations for industry leaders to integrate rapid molecular detection with confirmatory workflows, strengthen supply chains, and accelerate clinical adoption
Industry leaders should prioritize integrated diagnostic strategies that marry rapid molecular detection with confirmatory culture workflows to ensure both immediate clinical action and comprehensive resistance profiling. Investments in decentralized nucleic acid amplification platforms and enhanced sample-prep methods will reduce time to treatment and improve patient outcomes, while institutional commitment to biosafety and staff training will protect both patients and laboratory personnel.
Supply chain diversification and stronger contractual frameworks should be implemented to mitigate tariff-related and logistics risks. Engaging with regional regulatory authorities early in the product lifecycle and investing in post-market evidence generation will accelerate reimbursement and adoption. Health systems should also evaluate distribution models that leverage diagnostic laboratories, hospital pharmacies, and online procurement channels to expand access while maintaining quality controls. Finally, manufacturers and health systems can collaborate on pilot implementations that demonstrate clinical utility in real-world pathways, creating the evidence base needed to scale solutions sustainably.
A rigorous mixed-methods research methodology combining primary stakeholder interviews, secondary literature synthesis, and robust validation to ensure actionable findings
This research synthesizes primary stakeholder input, secondary scientific literature, regulatory documents, and validated device specifications to produce a rigorous and transparent methodology. Primary research included structured interviews with laboratory directors, clinical microbiologists, procurement leads, and regulatory affairs specialists to capture operational realities, procurement constraints, and evidence requirements. Secondary sources comprised peer-reviewed articles, clinical guidelines, and publicly available regulatory filings that informed technology assessments and clinical performance characterization.
Data triangulation and cross-validation ensured consistency across information sources, with particular attention to assay sensitivity profiles, sample-type performance, and biosafety implications. The methodology incorporated qualitative analysis to interpret adoption barriers and enablers, and it applied a risk assessment framework to evaluate supply chain vulnerabilities and regulatory complexity. Quality control measures included expert review panels and iterative validation of key findings with frontline clinical stakeholders to ensure relevance and accuracy for decision-makers.
Conclusion synthesizing technological advances, operational imperatives, and strategic priorities to translate diagnostic innovations into clinical and public health impact
In conclusion, the tuberculosis testing environment is at an inflection point where technological possibility meets operational necessity. Advances in nucleic acid amplification, point-of-care rapid assays, and improvements in immunodiagnostics and culture workflows offer multiple avenues to accelerate diagnosis and optimize treatment pathways. However, realizing these benefits requires coordinated investment in laboratory capacity, workforce training, supply chain resilience, and regulatory engagement to translate innovative assays into routine clinical practice.
Decision-makers should approach diagnostic strategy holistically, integrating rapid screening with confirmatory testing, aligning procurement with operational capabilities, and building the evidence base needed for reimbursement and public health adoption. The interplay between regional dynamics, tariff pressures, and technological choices underscores the need for flexible strategies that are responsive to local constraints while leveraging global innovations. Ultimately, actionable planning and collaborative execution will determine the degree to which diagnostic advances translate into measurable improvements in patient outcomes and public health impact.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid molecular testing platforms integrated with AI enabled decision support for multi drug resistant TB detection in remote clinics
- 5.2. Expansion of point of care immunodiagnostic assays targeting latent tuberculosis infection detection in community outreach programs
- 5.3. Increased regulatory approvals and government funding incentives accelerating development of next generation CRISPR based TB diagnostic tests
- 5.4. Integration of smartphone microscopy and cloud based data analytics for remote tuberculosis smear examination and monitoring
- 5.5. Scaling of fully automated sample to answer nucleic acid amplification platforms to reduce turnaround time in high burden regions
- 5.6. Collaboration between pharmaceutical companies and public health agencies to expand mass screening initiatives in urban slums
- 5.7. Adoption of multiplexed biomarker panels combining host immune response and pathogen detection for improved TB diagnosis accuracy
- 5.8. Implementation of decentralized testing networks utilizing mobile laboratories to address TB outbreaks in remote communities
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Tuberculosis Testing Market, by Test Type
- 8.1. Culture Test
- 8.1.1. Liquid Culture
- 8.1.2. Solid Culture
- 8.2. Immunological Test
- 8.2.1. Elisa
- 8.2.2. Western Blot
- 8.3. Molecular Test
- 8.3.1. Line Probe Assay
- 8.3.2. Pcr
- 8.4. Rapid Diagnostic Test
- 8.4.1. Chromatographic
- 8.4.2. Lateral Flow
- 9. Tuberculosis Testing Market, by Technology
- 9.1. Culture Based Technology
- 9.2. Immunodiagnostic
- 9.3. Lipoarabinomannan Assay
- 9.4. Nucleic Acid Amplification Test
- 10. Tuberculosis Testing Market, by Sample Type
- 10.1. Blood
- 10.2. Sputum
- 10.3. Urine
- 11. Tuberculosis Testing Market, by End User
- 11.1. Clinics
- 11.2. Hospitals
- 11.3. Reference Laboratory
- 12. Tuberculosis Testing Market, by Distribution Channel
- 12.1. Diagnostic Laboratory
- 12.2. Hospital Pharmacy
- 12.3. Online Pharmacy
- 13. Tuberculosis Testing Market, by Application
- 13.1. Active Tuberculosis
- 13.2. Latent Tuberculosis
- 14. Tuberculosis Testing Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Tuberculosis Testing Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Tuberculosis Testing Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Cepheid, Inc.
- 17.3.2. QIAGEN N.V.
- 17.3.3. Hain Lifescience GmbH
- 17.3.4. Roche Diagnostics International Ltd
- 17.3.5. Abbott Laboratories
- 17.3.6. Becton Dickinson and Company
- 17.3.7. Bio-Rad Laboratories, Inc.
- 17.3.8. Thermo Fisher Scientific Inc.
- 17.3.9. Siemens Healthineers AG
- 17.3.10. bioMérieux SA
- 17.3.11. Serum Institute of India
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
